Quick Answer
Vir Biotechnology, Inc. reported Total Revenue of $68.56 million for the year ending 2025.
- Vir Biotechnology, Inc. showed a decrease of -7.6% in Total Revenue from 2024 to 2025.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $2.43 million | Q2 2018: $2.22 million | Q3 2018: $2.89 million | Q4 2018: $3.13 million | Q1 2019: $3.66 million | Q2 2019: $2.05 million | Q3 2019: $1.40 million | Q4 2019: $980.0 thousand | Q1 2020: $5.72 million | Q2 2020: $66.99 million | Q3 2020: $1.93 million | Q4 2020: $1.73 million | Q1 2021: $1.98 million | Q2 2021: $177.07 million | Q3 2021: $103.62 million | Q1 2022: $1.23 billion | Q2 2022: -$40.63 million | Q3 2022: $374.56 million | Q1 2023: $62.96 million | Q2 2023: $3.80 million | Q3 2023: $2.64 million | Q1 2024: $56.38 million | Q2 2024: $3.08 million | Q3 2024: $2.38 million | Q1 2025: $3.03 million | Q2 2025: $1.21 million | Q3 2025: $240.0 thousand.
- Over the full 9 years of available data (2017 to 2025), Vir Biotechnology, Inc.'s Total Revenue has grown by 2,431.6%.
- Historical annual values: Fiscal year 2025: $68.56 million | Fiscal year 2024: $74.21 million | Fiscal year 2023: $86.18 million | Fiscal year 2022: $1.62 billion | Fiscal year 2021: $1.10 billion | Fiscal year 2020: $76.37 million | Fiscal year 2019: $8.09 million | Fiscal year 2018: $10.67 million | Fiscal year 2017: $2.71 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: